Researchers reported a rare case of familial amyloid polyneuropathy (FAP) in a patient with TRR gene Val30Met mutation who was experiencing impaired upper limb…
News
A parameter called electrochemical skin conductance is linked to disease severity in patients with familial amyloid polyneuropathy (FAP), potentially supporting the use of a…
Blood vessel abnormalities in the eye’s structures are common features in patients with familial amyloid polyneuropathy (FAP) caused by the Val30Met genetic mutation, according…
As President Trump signed the recently passed Right to Try legislation into law in a White House ceremony, Jordan McLinn of Indianapolis tried twice to…
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tegsedi (inotersen) as a treatment for Stage 1…
Finding treatments and potential cures for rare diseases is crucial, but so is the quality of patients’ lives — a rather nebulous term that means…
Vyndaqel (tafamidis) failed to prevent the progressive accumulation of abnormal transthyretin protein in a patient with a rare variant of familial amyloid polineuropahy (FAP), also…
The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner…
The European Union isn’t doing enough to protect the 30 million or so people with rare diseases who live in its 28 member countries, officials…
Researchers identified a very rare mutation in a Libyan man who was diagnosed with late-onset familial amyloid polyneuropathy (FAP), according to a case report.
Recent Posts
- Scientists ID blood markers that predict heart risk in ATTR-CM
- Navigating amyloidosis treatment can be challenging for older adults
- Tiny skin biopsies may help diagnose transthyretin amyloidosis: New study
- Early diagnosis, treatment improves survival in ATTR-CM: Study
- FDA lifts clinical hold on Phase 3 trial of nex-z for hATTR-PN